UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Enrolling By Invitation
99 years or below
All
Phase
2
60 participants needed
1 Location
Brief description of study
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
